Inventor · disambiguated record
William Brady
Also filed as: BRADY WILLIAM · BRADY WILLIAM A
26 granted patents·24 pending applications·3,174 citations·filing 1993–2024
98Inventor score
Files withBRISTOL MYERS SQUIBB CO20EMERGENT PRODUCT DEV SEATTLE4TAN PHILIP4TRUBION PHARMACEUTICALS INC4APTEVO RES & DEVELOPMENT LLC3
Top patents by PatentIndex Score
50 records- 0199US5977318ACTLA4 receptor and uses thereofBRISTOL MYERS SQUIBB CO·Filed 1995·Granted Nov 2, 1999·438 cites·4 claims
- 0298US5844095ACTLA4 Ig fusion proteinsBRISTOL MYERS SQUIBB CO·Filed 1995·Granted Dec 1, 1998·417 cites·2 claims
- 0398US5434131AChimeric CTLA4 receptor and methods for its useBRISTOL MYERS SQUIBB CO·Filed 1993·Granted Jul 18, 1995·374 cites·8 claims
- 0497US5968510ACTLA4 receptor and uses thereofBRISTOL MYERS SQUIBB CO·Filed 1996·Granted Oct 19, 1999·157 cites·1 claims
- 0597US5885796ACTLA4 receptor and uses thereofBRISTOL MYERS SQUIBB CO·Filed 1995·Granted Mar 23, 1999·199 cites·12 claims
- 0697US5580756AB7Ig fusion proteinBRISTOL MYERS SQUIBB CO·Filed 1994·Granted Dec 3, 1996·238 cites·3 claims
- 0797US5521288ACD28IG fusion proteinBRISTOL MYERS SQUIBB CO·Filed 1994·Granted May 28, 1996·233 cites·2 claims
- 0896US7311910B2Methods for treating cancer and infectious disease by blocking CTLA4-B7 interactionsBRISTOL MYERS SQUIBB CO·Filed 2003·Granted Dec 25, 2007·40 cites·9 claims
- 0996US5851795ASoluble CTLA4 molecules and uses thereofBRISTOL MYERS SQUIBB CO·Filed 1995·Granted Dec 22, 1998·182 cites·21 claims
- 1096US5770197AMethods for regulating the immune response using B7 binding molecules and IL4-binding moleculesBRISTOL MYERS SQUIBB CO·Filed 1993·Granted Jun 23, 1998·200 cites·11 claims
- 1195US8409577B2Single chain multivalent binding proteins with effector functionTHOMPSON PETER ARMSTRONG·Filed 2007·Granted Apr 2, 2013·140 cites·17 claims
- 1295US6090914ACTLA4/CD28Ig hybrid fusion proteins and uses thereofBRISTOL MYERS SQUIBB CO·Filed 1994·Granted Jul 18, 2000·149 cites·7 claims
- 1394US7105166B1Soluble CTLA4 mutant molecules and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2000·Granted Sep 12, 2006·33 cites·12 claims
- 1494US6830937B1Method for generating and identifying antibodies directed against a B7BRISTOL MYERS SQUIBB CO·Filed 2000·Granted Dec 14, 2004·39 cites·5 claims
- 1593US6887471B1Method to inhibit T cell interactions with soluble B7BRISTOL MYERS SQUIBB CO·Filed 1999·Granted May 3, 2005·66 cites·5 claims
- 1693US5885579ACTLA4 receptor and uses thereofBRISTOL MYERS SQUIBB CO·Filed 1997·Granted Mar 23, 1999·122 cites·11 claims
- 1791US7572772B2Soluble CTLA4 mutant moleculesBRISTOL MYERS SQUIBB CO·Filed 2007·Granted Aug 11, 2009·10 cites·6 claims
- 1890US6641809B1Method of regulating cellular processes mediated by B7 and CD28BRISTOL MYERS SQUIBB CO·Filed 1994·Granted Nov 4, 2003·84 cites·16 claims
- 1987US8333966B2CD37 immunotherapeutics and uses thereofTAN PHILIP·Filed 2009·Granted Dec 18, 2012·14 cites·4 claims
- 2086US9101609B2CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereofTAN PHILIP·Filed 2009·Granted Aug 11, 2015·13 cites·5 claims
- 2182US9884921B2Bispecific heterodimeric diabodies and uses thereofPFIZER·Filed 2015·Granted Feb 6, 2018·4 cites·34 claims
- 2274US7070776B1Methods for blocking binding of CD28 receptor to B7BRISTOL MYERS SQUIBB CO·Filed 1995·Granted Jul 4, 2006·20 cites·7 claims
- 2374US2020354447A1Single-chain multivalent binding proteins with effector functionAPTEVO RES & DEVELOPMENT LLC·Filed 2019·Application pending·0 cites
- 2470US2009317397A1Soluble CTLA4 mutant molecules and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2009·Application pending·0 cites
- 2570US2024350835A1Humanized anti-prostate -specific membrane antigen (psma) antibody drug conjugatesAMBRX INC·Filed 2024·Application pending·0 cites
- 2667US10307481B2CD37 immunotherapeutics and uses thereofGROSMAIRE LAURA S·Filed 2006·Granted Jun 4, 2019·1 cites·14 claims
- 2765US12059473B2Humanized anti-prostate -specific membrane antigen (PSMA) antibody drug conjugatesAMBRX INC·Filed 2019·Granted Aug 13, 2024·0 cites·22 claims
- 2865US2009175867A1Single-Chain Multivalent Binding Proteins with Effector FunctionTRUBION PHARMACEUTICALS INC·Filed 2008·Application pending·0 cites
- 2964US2009214539A1B-cell reduction using cd37-specific and cd20-specific binding moleculesTRUBION PHARMACEUTICALS INC·Filed 2009·Application pending·0 cites
- 3063US10202447B2Antibody derivativesMEDIMMUNE LTD·Filed 2015·Granted Feb 12, 2019·1 cites·6 claims
- 3163US2018118823A1Single-chain multivalent binding proteins with effector functionAPTEVO RES & DEVELOPMENT LLC·Filed 2017·Application pending·0 cites
- 3261US2013336977A1Single-chain multivalent binding proteins with effector functionEMERGENT PRODUCT DEV SEATTLE·Filed 2013·Application pending·0 cites
- 3361US2014127203A1Single-chain multivalent binding proteins effector functionTHOMPSON PETER ARMSTRONG·Filed 2013·Application pending·0 cites
- 3461US2014141022A1Single-chain multivalent binding proteins with effector functionTHOMPSON PETER ARMSTRONG·Filed 2013·Application pending·0 cites
- 3560US2014154250A1Single-chain multivalent binding proteins with effector functionEMERGENT PRODUCT DEV SEATTLE·Filed 2013·Application pending·0 cites
- 3660US2014154252A1Single-chain multivalent binding proteins with effector functionEMERGENT PRODUCT DEV SEATTLE·Filed 2013·Application pending·0 cites
- 3759US2004253250A1Compositions and methods for regulating lymphocyte activationXCYTE THERAPIES INC·Filed 2003·Application pending·0 cites
- 3859US2019290755A1B-cell reduction using cd37-specific and cd20-specific binding moleculesAPTEVO RES & DEVELOPMENT LLC·Filed 2018·Application pending·0 cites
- 3956US10143748B2B-cell reduction using CD37-specific and CD20-specific binding moleculesEMERGENT PRODUCT DEV SEATTLE·Filed 2013·Granted Dec 4, 2018·0 cites·8 claims
- 4053US2014086903A1Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereofTAN PHILIP·Filed 2013·Application pending·0 cites
- 4153US2013195850A1Cd3 immunotherapeutics and uses thereofTAN PHILIP·Filed 2012·Application pending·0 cites
- 4251US2005261478A1Compositions and methods for regulating lymphocyte activationXCYTE THERAPIES INC·Filed 2005·Application pending·0 cites
- 4351US2003219446A1Ligand for CD28 receptor on B cells and methodsBRISTOL MYERS SQUIBB CO·Filed 2003·Application pending·0 cites
- 4449US2008279850A1B-Cell Reduction Using CD37-Specific and CD20-Specific Binding MoleculesTRUBION PHARMACEUTICALS INC·Filed 2008·Application pending·0 cites
- 4549US2009148447A1Binding Peptides Having a C-terminally Disposed Specific Binding DomainTRUBION PHARMACEUTICALS INC·Filed 2008·Application pending·0 cites
- 4648US2010330089A1Anti-cd20 therapeutic compositions and methodsWYETH CORP·Filed 2008·Application pending·0 cites
- 4747US2018155452A1Bispecific heterodimeric diabodies and uses thereofPFIZER·Filed 2017·Application pending·0 cites
- 4838US2014127209A1Antibody derivativesGRABSTEIN KENNETH·Filed 2013·Application pending·0 cites
- 4938US2022089768A1Multi-specific protein molecules and uses thereofTRIO PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 5028US2002155604A1Compositions and methods for regulating lymphocyte activationFiled 1999·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when William Brady files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →